Navigation Links
AtriCure Reports Record Second Quarter 2008 Financial Results
Date:8/5/2008

8,143,247 9,834,994

Stockholders' equity:

Common stock 14,196 14,132

Additional paid-in capital 104,899,820 103,524,814

Other comprehensive income 57,165 5,286

Accumulated deficit (72,505,779) (67,307,730)

Total stockholders' equity 32,465,402 36,236,502

Total liabilities and

stockholders' equity $40,608,649 $46,071,496

ATRICURE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Six Months Ended June 30,

2008 2007

Cash flows from operating activities:

Net loss $(5,198,047) $(7,089,511)

Adjustments to reconcile net loss to

net cash used in operating activities:

Depreciation and amortization 1,423,711 1,046,280

Loss on disposal of equipment - 6,852

Provision for (benefit from) losses

in accounts receivable 12,397 (99,720)

Share-based compensation expense 1,142,123 882,999

Changes in assets and liabilities,

excluding effects of acquired business:

Accounts receivable (2,192,408) (585,842)

Inventories (556,362) (586,742)

Other current assets 92,879 255,872

Accounts payable and accrued

liabilities (1,234,568) 293,955

Other non-current assets and

liabilities
'/>"/>

SOURCE AtriCure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AtriCure Announces Web Cast and Conference Call of Second Quarter 2008 Financial Results
2. AtriCure Reports First Quarter 2008 Financial Results
3. AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
4. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
5. eResearchTechnology Reports Second Quarter 2008 Results
6. SuperGen Reports 2008 Second Quarter Financial Results
7. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
8. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
9. CV Therapeutics Reports 2008 Second Quarter Financial Results
10. Gentiva Reports Strong Second Quarter led by Home Health Segment
11. United Therapeutics Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... TX (PRWEB) , ... July 29, 2015 , ... ... designer, manufacturer and supplier, announces the launch of their 2nd generation cell therapy ... the current miniPOD CT, but it also represents a new POD® design. ...
(Date:7/29/2015)... CHICAGO , July 29, 2015  AmnioChor Inc., ... cell technology, is very pleased to announce that the ... has agreed to invest in their seed round ... OmniBank placental tissue storage capabilities. AmnioChor,s ... placenta, and the human stem cells living within those ...
(Date:7/29/2015)... 2015  Indivior PLC (LON: INDV) today announced that ... was accepted and received Priority Review by the U.S. ... opioid overdose. This naloxone nasal spray comes as a ... absorption into the nasal mucosa. 1 The device ... may be better equipped to help an opioid overdose ...
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... has selected an optimized Erk inhibitor molecule for ... development of a new class of potential cancer ... a prime target for therapeutic intervention in cancer. ... survival benefits for B-Raf and Mek inhibitors. Erk ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... developing solutions based on the products of newborn fibroblasts, today launched ... culturing kit for stem cell growth. The kit was launched and ... place in Madison, Wisconsin. , ... San Diego, CA ...
... northern China indicates that genetically modified cotton, altered to express ... crops, but also reduces pests among other nearby crops that ... promising new ideas for controlling pests and maximizing crop yields ... by the journal Science on Friday, 19 September. ...
... a significant milestone for the growing open source clincial trials ... towards the needs of regulated industry sponsored clinical trials. ... ... 2008 -- Akaza Research announces the availability of OpenClinica 2.5, ...
Cached Biology Technology:Histogen Launches BioNuesis, the Only All-Human Stem Cell Culturing Kit 2Histogen Launches BioNuesis, the Only All-Human Stem Cell Culturing Kit 3GM crops protect neighbors from pests 2Akaza Research Releases New Version of OpenClinica Electronic Data Capture (EDC) Software; Targets Industry Clinical Trials 2Akaza Research Releases New Version of OpenClinica Electronic Data Capture (EDC) Software; Targets Industry Clinical Trials 3
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ... America Biomedical Sensors Market - Growth, Trends & Forecasts ... Latin America Biomedical Sensors market is estimated at $0.65 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
(Date:6/24/2015)... , June 22, 2015 ... the addition of the "Huawei Ascend Mate ... report to their offering. Huawei,s technological ... the opposite direction than Apple,s and Samsung,s one. ... sensor developed by Fingerprint Cards, a main actor ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2TAKE Solutions Awarded Patent By USPTO 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... nature when scientists succeeded in creating a new type ... occurring enzyme has evolved. This achievement opens the door ... in medicine and industry. Enzymes are, without ... works of nature. These molecular machines which without ...
... FOR IMMEDIATE RELEASE Toward a new generation ... Accounts of Chemical Research Researchers in Colombia, ... next generation of synthetic vaccines that could lead to ... other infectious diseases. These conditions kill more than 17 ...
... the red flour beetle living happily in the flour sack ... University, and many others throughout the world, this pest of ... studying genetics. The superior status of this beetle, Tribolium ... work of two Kansas State University faculty, Susan Brown, professor ...
Cached Biology News:Birth of an enzyme 2Birth of an enzyme 3American Chemical Society's Weekly PressPac -- March 19, 2008 2American Chemical Society's Weekly PressPac -- March 19, 2008 3American Chemical Society's Weekly PressPac -- March 19, 2008 4American Chemical Society's Weekly PressPac -- March 19, 2008 5American Chemical Society's Weekly PressPac -- March 19, 2008 6American Chemical Society's Weekly PressPac -- March 19, 2008 7American Chemical Society's Weekly PressPac -- March 19, 2008 8American Chemical Society's Weekly PressPac -- March 19, 2008 9
Purified anti-PXR...
Polyclonal Antibody to PRG3...
Goat polyclonal to MLH3 ( Abpromise for all tested applications). entrezGeneID: 27030 SwissProtID: Q9UHC1...
Mouse monoclonal [2991] to C3a / C3a des Arg ( Abpromise for all tested applications). SwissProtID: P01024...
Biology Products: